Display options
Cite
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;7(5):1-101
(2007). Low-density lipoprotein apheresis: an evidence-based analysis. Ontario health technology assessment series, 7(5), 1-101.
"Low-density lipoprotein apheresis: an evidence-based analysis." Ontario health technology assessment series vol. 7,5 (2007): 1-101.
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01. PMID: 23074505; PMCID: PMC3377562.
Copy Download .nbib Format: NLM
Share it on

Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01.

Low-density lipoprotein apheresis: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]

PMID: 23074505 PMCID: PMC3377562

Abstract

OBJECTIVE: To assess the effectiveness and safety of low-density lipoprotein (LDL) apheresis performed with the heparin-induced extracorporeal LDL precipitation (HELP) system for the treatment of patients with refractory homozygous (HMZ) and heterozygous (HTZ) familial hypercholesterolemia (FH). BACKGROUND ON FAMILIAL HYPERCHOLESTEROLEMIA: Familial hypercholesterolemia is a genetic autosomal dominant disorder that is caused by several mutations in the LDL-receptor gene. The reduced number or absence of functional LDL receptors results in impaired hepatic clearance of circulating low-density lipoprotein cholesterol (LDL-C) particles, which results in extremely high levels of LDL-C in the bloodstream. Familial hypercholesterolemia is characterized by excess LDL-C deposits in tendons and arterial walls, early onset of atherosclerotic disease, and premature cardiac death. Familial hypercholesterolemia occurs in both HTZ and HMZ forms. Heterozygous FH is one of the most common monogenic metabolic disorders in the general population, occurring in approximately 1 in 500 individuals. Nevertheless, HTZ FH is largely undiagnosed and an accurate diagnosis occurs in only about 15% of affected patients in Canada. Thus, it is estimated that there are approximately 3,800 diagnosed and 21,680 undiagnosed cases of HTZ FH in Ontario. In HTZ FH patients, half of the LDL receptors do not work properly or are absent, resulting in plasma LDL-C levels 2- to 3-fold higher than normal (range 7-15mmol/L or 300-500mg/dL). Most HTZ FH patients are not diagnosed until middle age when either they or one of their siblings present with symptomatic coronary artery disease (CAD). Without lipid-lowering treatment, 50% of males die before the age of 50 and 25% of females die before the age of 60, from myocardial infarction or sudden death. In contrast to the HTZ form, HMZ FH is rare (occurring in 1 case per million persons) and more severe, with a 6- to 8-fold elevation in plasma LDL-C levels (range 15-25mmol/L or 500-1000mg/dL). Homozygous FH patients are typically diagnosed in infancy, usually due to the presence of cholesterol deposits in the skin and tendons. The main complication of HMZ FH is supravalvular aortic stenosis, which is caused by cholesterol deposits on the aortic valve and in the ascending aorta. The average life expectancy of affected individuals is 23 to 25 years. In Ontario, it is estimated that there are 13 to 15 cases of HMZ FH. An Ontario clinical expert confirmed that 9 HMZ FH patients have been identified to date.

DIAGNOSIS: There are 2 accepted clinical diagnostic criterion for the diagnosis of FH: the Simon Broome FH Register criteria from the United Kingdom and the Dutch Lipid Network criteria from the Netherlands. The criterion supplement cholesterol levels with clinical history, physical signs and family history. DNA-based-mutation-screening methods permit a definitive diagnosis of HTZ FH to be made. However, given that there are over 1000 identified mutations in the LDL receptor gene and that the detection rates of current techniques are low, genetic testing becomes problematic in countries with high genetic heterogeneity, such as Canada.

TREATMENT: The primary aim of treatment in both HTZ and HMZ FH is to reduce plasma LDL-C levels in order to reduce the risk of developing atherosclerosis and CAD. The first line of treatment is dietary intervention, however it alone is rarely sufficient for the treatment of FH patients. Patients are frequently treated with lipid-lowering drugs such as resins, fibrates, niacin, statins and cholesterol absorption-inhibiting drugs (ezetimibe). Most HTZ FH patients require a combination of drugs to achieve or approach target cholesterol levels. A small number of HTZ FH patients are refractory to treatment or intolerant to lipid-lowering medication. According to clinical experts, the prevalence of refractory HTZ FH in Ontario is between 1 to 5%. Using the mean of 3%, it is estimated that there are approximately 765 refractory HTZ FH patients in Ontario, of which 115 are diagnosed and 650 are undiagnosed. Drug therapy is less effective in HMZ FH patients since the effects of the majority of cholesterol-lowering drugs are mediated by the upregulation of LDL receptors, which are often absent or function poorly in HMZ FH patients. Some HMZ FH patients may still benefit from drug therapy, however this rarely reduces LDL-C levels to targeted levels. EXISTING TECHNOLOGY: PLASMA EXCHANGE An option currently available in Ontario for FH patients who do not respond to standard diet and drug therapy is plasma exchange (PE). Patients are treated with this lifelong therapy on a weekly or biweekly basis with concomitant drug therapy. Plasma exchange is nonspecific and eliminates virtually all plasma proteins such as albumin, immunoglobulins, coagulation factors, fibrinolytic factors and HDL-C, in addition to acutely lowering LDL-C by about 50%. Blood is removed from the patient, plasma is isolated, discarded and replaced with a substitution fluid. The substitution fluid and the remaining cellular components of the blood are then returned to the patient. The major limitation of PE is its nonspecificity. The removal of HDL-C prevents successful vascular remodeling of the areas stenosed by atherosclerosis. In addition, there is an increased susceptibility to infections, and costs are incurred by the need for replacement fluid. Adverse events can be expected to occur in 12% of procedures. OTHER ALTERNATIVES: Surgical alternatives for FH patients include portocaval shunt, ileal bypass and liver transplantation. However, these are risky procedures and are associated with a high morbidity rate. Results with gene therapy are not convincing to date.

THE TECHNOLOGY BEING REVIEWED: LDL APHERESIS An alternative to PE is LDL apheresis. Unlike PE, LDL apheresis is a selective treatment that removes LDL-C and other atherogenic lipoproteins from the blood while minimally impacting other plasma components such as HDL-C, total serum protein, albumin and immunoglobulins. As with PE, FH patients require lifelong therapy with LDL apheresis on a weekly/biweekly basis with concomitant drug therapy. HEPARIN-INDUCED EXTRACORPOREAL LDL PRECIPITATION: Heparin-induced extracorporeal LDL precipitation (HELP) is one of the most widely used methods of LDL apheresis. It is a continuous closed-loop system that processes blood extracorporeally. It operates on the principle that at a low pH, LDL and lipoprotein (a) [Lp(a)] bind to heparin and fibrinogen to form a precipitate which is then removed by filtration. In general, the total duration of treatment is approximately 2 to 3 hours. Results from early trials indicate that LDL-C concentration is reduced by 65% to 70% immediately following treatment in both HMZ and HTZ FH and then rapidly begins to rise. Typically patients with HTZ FH are treated every 2 weeks while patients with HMZ FH require weekly therapy. Heparin-induced extracorporeal LDL precipitation also produces small transient decreases in HDL-C, however levels generally return to baseline within 2 days. After several months of therapy, long-term reductions in LDL-C and increases in HDL-C have been reported. In addition to having an impact on plasma cholesterol concentrations, HELP lowers plasma fibrinogen, a risk factor for atherosclerosis, and reduces concentrations of cellular adhesion molecules, which play a role in early atherogenesis. In comparison with PE, HELP LDL apheresis does not have major effects on essential plasma proteins and does not require replacement fluid, thus decreasing susceptibility to infections. One study noted that adverse events were documented in 2.9% of LDL apheresis treatments using the HELP system compared with 12% using PE. As per the manufacturer, patients must weigh at least 30kgs to be eligible for treatment with HELP.

REGULATORY STATUS: The H.E.L.P.® System (B.Braun Medizintechnologie GmbH, Germany) has been licensed by Health Canada since December 2000 as a Class 3 medical device (Licence # 26023) for performing LDL apheresis to acutely remove LDL from the plasma of 3 high-risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated. The 3 patient groups are as follows: Functional hypercholesterolemic homozygotes with LDL-C >500 mg/dL (>13mmol/L);Functional hypercholesterolemic heterozygotes with LDL-C >300 mg/dL (>7.8mmol/L);Functional hypercholesterolemic heterozygotes with LDL-C >200 mg/dL (>5.2mmol/L) and documented CADNo other LDL apheresis system is currently licensed in Canada.

REVIEW STRATEGY: The Medical Advisory Secretariat systematically reviewed the literature to assess the effectiveness and safety of LDL apheresis performed with the HELP system for the treatment of patients with refractory HMZ and HTZ FH. A standard search methodology was used to retrieve international health technology assessments and English-language journal articles from selected databases. The GRADE approach was used to systematically and explicitly make judgments about the quality of evidence and strength of recommendations.

SUMMARY OF FINDINGS: The search identified 398 articles published from January 1, 1998 to May 30, 2007. Eight studies met the inclusion criteria. Five case series, 2 case series nested within comparative studies, and one retrospective review, were included in the analysis. A health technology assessment conducted by the Alberta Heritage Foundation for Medical Research, and a review by the United States Food and Drug Administration were also included. Large heterogeneity among the studies was observed. Studies varied in inclusion criteria, baseline patient characteristics and methodology. Overall, the mean acute relative decrease in LDL-C with HELP LDL apheresis ranged from 53 to 77%. The mean acute relative reductions ranged as follows: total cholesterol (TC) 47 to 64%, HDL-C +0. (ABSTRACT TRUNCATED)

References

  1. Hum Mutat. 1992;1(6):445-66 - PubMed
  2. Circulation. 2002 May 28;105(21):2469-75 - PubMed
  3. Am Heart J. 1999 Mar;137(3):410-8 - PubMed
  4. Arteriosclerosis. 1989 Jan-Feb;9(1 Suppl):I152-7 - PubMed
  5. Ther Apher. 2001 Jun;5(3):207-11 - PubMed
  6. BMJ. 2000 Jul 15;321(7254):148 - PubMed
  7. Lancet. 1998 Nov 21;352(9141):1643-4 - PubMed
  8. Curr Opin Lipidol. 2002 Apr;13(2):165-71 - PubMed
  9. Atherosclerosis. 2003 May;168(1):1-14 - PubMed
  10. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed
  11. Am Heart J. 1991 Jan;121(1 Pt 2):293-8 - PubMed
  12. Ther Apher. 1999 Aug;3(3):203-8 - PubMed
  13. J Artif Organs. 2003;6(1):1-8 - PubMed
  14. Int J Artif Organs. 2002 Dec;25(12):1180-8 - PubMed
  15. Cardiovasc Drugs Ther. 2002 Jul;16(4):289-93 - PubMed
  16. Am J Cardiol. 1998 Dec 15;82(12):1489-95 - PubMed
  17. Health Technol Assess. 2000;4(29):1-123 - PubMed
  18. Ann Med. 1999 Apr;31 Suppl 1:13-8 - PubMed
  19. Am J Cardiol. 1998 Feb 15;81(4):407-11 - PubMed
  20. BMJ. 1991 Oct 12;303(6807):893-6 - PubMed
  21. Ther Apher. 2001 Oct;5(5):387-93 - PubMed
  22. Acta Medica (Hradec Kralove). 2003;46(1):3-7 - PubMed
  23. Circulation. 1992 Jan;85(1):37-45 - PubMed
  24. Ther Apher Dial. 2003 Aug;7(4):397-401 - PubMed
  25. Ther Apher Dial. 2005 Apr;9(2):142-7 - PubMed
  26. Am J Med. 1990 Feb;88(2):94-100 - PubMed
  27. Artif Organs. 1996 Apr;20(4):303-10 - PubMed
  28. Int J Artif Organs. 2004 Feb;27(2):137-48 - PubMed
  29. Clin Chem. 2004 Oct;50(10):1725-32 - PubMed
  30. Transfus Apher Sci. 2004 Jun;30(3):233-43 - PubMed
  31. Artif Organs. 2005 Jan;29(1):47-52 - PubMed
  32. Am J Cardiol. 1995 Jun 1;75(16):1124-9 - PubMed
  33. CMAJ. 2006 Apr 11;174(8):1124-9 - PubMed
  34. Atherosclerosis. 2006 Nov;189(1):31-8 - PubMed
  35. BMJ. 2001 Apr 28;322(7293):1019-23 - PubMed
  36. Nurs Stand. 2005 Dec 14-2006 Jan 3;20(14-16):55-65; quiz 66 - PubMed
  37. Mayo Clin Proc. 2001 Oct;76(10):1039-46 - PubMed
  38. Ther Apher Dial. 2003 Jun;7(3):365-9 - PubMed
  39. Cardiol Young. 2002 Mar;12(2):105-12 - PubMed
  40. Int J Cardiol. 2003 May;89(1):13-23 - PubMed
  41. Eur Heart J. 1998 Oct;19(10):1434-503 - PubMed
  42. Am J Cardiol. 2005 Aug 22;96(4A):67E-69E - PubMed
  43. Ther Apher Dial. 2003 Aug;7(4):378-81 - PubMed
  44. CMAJ. 2003 Oct 28;169(9):921-4 - PubMed
  45. CMAJ. 1990 Mar 15;142(6):557-62 - PubMed
  46. Atherosclerosis. 2000 Oct;152(2):519-26 - PubMed
  47. Eur J Clin Invest. 1994 Nov;24(11):724-32 - PubMed
  48. Ther Apher Dial. 2006 Dec;10(6):510-7 - PubMed
  49. N Engl J Med. 2007 Jan 11;356(2):148-56 - PubMed
  50. Am J Cardiol. 2005 May 15;95(10):1246-7 - PubMed
  51. Am J Cardiol. 2004 Apr 15;93(8):1044-6 - PubMed
  52. Atherosclerosis. 2003 Mar;167(1):1-13 - PubMed
  53. Transfus Apher Sci. 2003 Oct;29(2):167-77 - PubMed
  54. Transfus Apher Sci. 2004 Jun;30(3):255-66 - PubMed
  55. Atherosclerosis. 2005 May;180(1):107-12 - PubMed
  56. Curr Treat Options Cardiovasc Med. 2006 Aug;8(4):282-8 - PubMed
  57. Ther Apher Dial. 2005 Dec;9(6):459-68 - PubMed
  58. Ther Apher Dial. 2004 Feb;8(1):33-8 - PubMed
  59. Semin Vasc Med. 2004 Feb;4(1):31-41 - PubMed
  60. BMJ. 2004 Jun 19;328(7454):1490 - PubMed
  61. Int J Artif Organs. 2005 Oct;28(10):1025-31 - PubMed
  62. Atherosclerosis. 2000 Nov;153(1):89-98 - PubMed
  63. Ther Apher Dial. 2003 Aug;7(4):382-90 - PubMed
  64. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  65. Am J Cardiol. 2003 Feb 15;91(4):461-4 - PubMed
  66. Atherosclerosis. 2001 Oct;158(2):495-8 - PubMed
  67. Genome. 2006 Nov;49(11):1343-50 - PubMed
  68. Atherosclerosis. 1995 Apr 24;114(2):203-11 - PubMed
  69. Ther Apher. 2002 Jun;6(3):229-33 - PubMed
  70. Cochrane Database Syst Rev. 2001;(2):CD001918 - PubMed
  71. Heart Lung Circ. 2007 Feb;16(1):25-7 - PubMed
  72. Ther Apher. 1998 Aug;2(3):218-23 - PubMed
  73. Pediatrics. 2007 Jul;120(1):e189-214 - PubMed
  74. Transfus Apher Sci. 2004 Aug;31(1):3-10 - PubMed
  75. Br Med J (Clin Res Ed). 1985 Dec 14;291(6510):1671-3 - PubMed
  76. Atherosclerosis. 2002 May;162(1):187-91 - PubMed
  77. Isr J Med Sci. 1996 Jun;32(6):407-13 - PubMed
  78. Lancet. 2004 Sep 11-17;364(9438):937-52 - PubMed
  79. Atherosclerosis. 2004 Jul;175(1):145-50 - PubMed
  80. Ther Apher. 2001 Aug;5(4):221-5 - PubMed
  81. J Clin Apher. 2002;17(1):38-43 - PubMed
  82. Ther Apher Dial. 2003 Aug;7(4):402-7 - PubMed
  83. Am J Cardiol. 1993 Apr 1;71(10):816-22 - PubMed
  84. Can J Cardiol. 2006 Sep;22(11):913-27 - PubMed
  85. Transfus Apher Sci. 2004 Jun;30(3):213-20 - PubMed
  86. Semin Vasc Med. 2004 Feb;4(1):51-7 - PubMed
  87. Circulation. 2006 Dec 12;114(24):2710-38 - PubMed

Publication Types